Celgene (CELG) Acquires Abraxis BioScience (ABII) In a Deal Worth At Least $2.9 Billion
Tweet Send to a Friend
Celgene Corporation (NASDAQ: CELG) announced an agreement to acquire Abraxis BioScience Inc. (Nasdaq: ABII) in a deal worth $2.9 billion ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
